Linaclotide
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Linaclotide: From Chronic Constipation to Cauda Equina Syndrome
One-Sentence Summary
Linaclotide is a locally-acting gut peptide, established for treating IBS-C and chronic idiopathic constipation (based on general pharmacological knowledge; not captured in this evidence pack). The TxGNN model predicts it may be effective for Cauda Equina Syndrome, but no clinical trials and no literature currently support this direction, and the model’s own mechanistic review flags the link as likely spurious.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in evidence pack (generally known as IBS-C / chronic idiopathic constipation) |
| Predicted New Indication | Cauda Equina Syndrome |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed original mechanism-of-action data is not available in this evidence pack. Based on the repurposing rationale supplied alongside the prediction, linaclotide is a locally-acting guanylate cyclase-C (GC-C) receptor agonist confined to the intestinal epithelium, with minimal systemic absorption; its action increases chloride/bicarbonate secretion in the gut and has no known effect outside the intestinal lumen.
Cauda equina syndrome is a surgical emergency caused by mechanical compression of nerve roots below the spinal cord — a pathology with no established connection to the GC-C/cGMP signaling pathway linaclotide acts through. The evidence pack itself notes this prediction is most likely a graph artifact: a spurious “gut–nerve” node linkage arising from clinical co-occurrence of constipation and neurogenic bowel symptoms, rather than a genuine pharmacological mechanism.
Given the absence of any mechanistic plausibility, clinical trials, or literature, this prediction should be treated as a hypothesis-generation signal only, not as an actionable repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Linaclotide is currently not marketed under this registry, with no license records available in the evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a raw TxGNN model score (L5) with zero clinical trials, zero literature, and a mechanistic rationale that the evidence pack itself characterizes as likely noise rather than a genuine pharmacological link.
To proceed, the following is needed:
- Confirmed mechanism-of-action (MOA) data for linaclotide
- TFDA/label warnings and contraindications (currently blocking safety screening)
- Independent mechanistic or preclinical evidence connecting GC-C agonism to cauda equina pathology before any further evaluation
- Re-screening of lower-ranked candidates (e.g., neurogenic bladder, insomnia) — both also lack supporting evidence and carry similarly weak mechanistic justification
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.